BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

Published:2020-03-23 Issue:6 Volume:104 Page:594-601
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Mahlangu Johnny¹^ORCID,Lopez Fernandez Maria Fernanda²,Santagostino Elena³,Lalezari Shadan⁴⁵,Tseneklidou‐Stoeter Despina⁶,Beckmann Horst⁷,Church Nikki⁸

Affiliation:

1. Hemophilia Comprehensive Care Center Faculty of Health Sciences Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand, and National Health Laboratory Service Johannesburg South Africa

2. INIBIC‐C.H.U. A Coruña Complexo Hospitalario Universitario, Hospital Materno Infantil A Coruña Spain

3. Foundation IRCCS Ca’ Granda A. Bianchi Bonomi Hemophilia and Thrombosis Center Maggiore Hospital Policlinico Milan Italy

4. Israel National Haemophilia Center Chaim Sheba Medical Center Tel Hashomer Israel

5. Sackler School of Medicine Tel‐Aviv University Tel Aviv‐Yafo Israel

6. Bayer Berlin Germany

7. Bayer Wuppertal Germany

8. Bayer Whippany NJ USA

Funder

Bayer

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13402

Reference25 articles.

1. Guidelines for the management of hemophilia

2. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials;Journal of Blood Medicine;2023-06

2. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A;Current Medical Research and Opinion;2022-05-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3